Company Overview - ResMed is a medical equipment company based in San Diego, California, originally founded in Australia, specializing in cloud-connectable CPAP machines for obstructive sleep apnea treatment [1] - The company has over 10,000 employees and operates in more than 140 countries, with two primary business units: Sleep and Respiratory Care, and Software as a Service (SaaS) [2] - ResMed's SaaS unit provides software for durable or home medical equipment, assisting in out-of-hospital care [2][3] Financial Performance - ResMed reported an annual revenue of $4,685 million, with a compound annual growth rate (CAGR) of 13.6% over the last three years [5] - The latest reported gross margin for ResMed was 57.4%, indicating strong profitability from core products and services [6] - The company reported a profit of $1,021 million in the last financial year, up from $475 million three years ago, representing a CAGR of 29.1% [7] Financial Health - ResMed's current net debt is -$624 million, indicating that the company has more cash than debt, which can be seen as a safety buffer [9] - The debt/equity ratio for ResMed is 18.0%, suggesting that the company has more equity than debt, indicating lower leverage [10] - The return on equity (ROE) for ResMed was 22.7% in FY24, reflecting efficient capital allocation and value generation [11] Valuation Metrics - ResMed shares currently have a price-to-sales ratio of 5.69x, below the 5-year average of 8.70x, indicating that shares are trading below their historical average [12]

Core Viewpoint - Resmed will present at the Bank of America Global Healthcare Conference 2025, highlighting its commitment to innovative health technologies and solutions [1]. Company Information - Resmed (NYSE: RMD, ASX: RMD) focuses on creating life-changing health technologies aimed at improving the quality of life for individuals [3]. - The company is dedicated to pioneering innovative technology that empowers millions across 140 countries to lead healthier lives [3]. - Resmed's offerings include AI-powered digital health solutions, cloud-connected devices, and intelligent software designed to enhance home healthcare [3]. - The company's vision is to enable every individual to reach their full potential through improved sleep and breathing, with care provided in their own homes [3]. Event Details - Mick Farrell, the chairman and CEO, along with Dr. Carlos Nunez, the chief medical officer, will present at the conference on September 23, 2025, at approximately 1:20 p.m. British Summer Time in London [1]. - Additional information about the event, including access to a live audio-only webcast, can be found on Resmed's investor relations website [2]. - A replay of the audio-only webcast will be available approximately 24 hours after the live event and will remain accessible for 30 days [2].

Company Overview - ResMed Inc. is based in San Diego, California, and specializes in developing, manufacturing, distributing, and marketing medical devices and cloud-based software applications for respiratory disorders [1] - The company has a market capitalization of $39.6 billion and operates through two segments: Sleep and Breathing Health and Residential Care Software [1][2] Stock Performance - ResMed's stock reached a three-year high of $293.81 on August 22 and is currently trading 8.1% below that peak [3] - Over the past three months, RMD has gained 7.1%, outperforming the Health Care Select Sector SPDR Fund (XLV), which saw a marginal increase of 0.95% [3] - In 2025, RMD stock prices surged 18.1%, and over the past 52 weeks, they increased by 7.8%, while XLV experienced a slight uptick of 0.39% year-to-date and a decline of 11.4% over the past year [4] Financial Performance - Following the release of its Q4 results on July 31, ResMed's stock prices rose by 2.7% [5] - The company reported net revenues of $1.35 billion for the quarter, reflecting a year-over-year growth of 10.2%, surpassing Street expectations by 1.9% [5] - Non-GAAP EPS increased by 22.6% year-over-year to $2.55, exceeding consensus estimates by 3.7% [5] Competitive Position - ResMed has significantly outperformed its peer, Becton, Dickinson and Company (BDX), which saw a decline of 17.6% in 2025 and a 20.7% drop over the past 52 weeks [6] - The stock has a consensus "Moderate Buy" rating among 18 analysts, with a mean price target of $289.25, indicating a 7.1% upside potential from current price levels [6]

Company Overview - ResMed is a medical equipment company based in San Diego, California, originally founded in Australia, specializing in cloud-connectable CPAP machines for obstructive sleep apnea treatment [2] - The company operates globally with over 10,000 employees and a presence in more than 140 countries, divided into two primary business units: Sleep and Respiratory Care, and Software as a Service (SaaS) [3] - Netwealth is a wealth management software business that provides a platform for financial planners, with over 140,000 account holders and $88 billion in funds under administration as of 2024 [5] Business Model and Services - ResMed's Sleep and Respiratory Care unit offers industry-leading CPAP machines, catering to a wide range of patients from those needing nightly therapy to those requiring life-support ventilation [3] - The SaaS unit provides software for durable or home medical equipment, enhancing out-of-hospital care [3][4] - Netwealth's platform allows users to manage investments, track performance, and access financial reports through a user-friendly interface [6] Financial Performance and Valuation - ResMed shares have a current price-sales ratio of 5.63x, significantly lower than its 5-year average of 8.70x, indicating potential undervaluation or increased sales [8] - In contrast, Netwealth shares trade at a price-sales ratio of 30.23x, above its 5-year average of 23.72x, suggesting a higher valuation relative to historical performance [9]

Company Overview - ResMed Inc. (NYSE:RMD) is a leading health technology company focused on sleep, breathing, and home care solutions, developing innovative devices and digital platforms for patients with sleep apnea and chronic respiratory conditions [1] - The company aims to improve patient outcomes globally by combining medical expertise with advanced technology [1] Recent Developments - In 2025, ResMed launched its Sleep Institute at the World Sleep Congress, aiming to advance sleep health through partnerships with various stakeholders, focusing on evidence-based insights to drive care innovation [2] - The initiative addresses the global burden of sleep disorders, particularly obstructive sleep apnea (OSA) and insomnia, which are often undiagnosed [2] Research and Trends - Research presented at the SLEEP 2025 conference highlighted trends such as PAP therapy adherence, gender disparities in OSA diagnosis, patient-reported outcomes, and the role of artificial intelligence in enhancing therapy engagement [3] - These developments position ResMed as a strong growth potential player in the health technology sector through innovation in devices and digital health solutions [3] Strategic Acquisitions - ResMed acquired VirtuOx, an independent diagnostic testing facility specializing in at-home diagnostics for sleep, respiratory, and cardiac conditions, enhancing its capabilities in early diagnosis and connected home-based care [4] - This acquisition simplifies patient access and supports better health outcomes [4]

Core Insights - The importance of sleep is increasingly recognized as a critical pillar of human health alongside diet and exercise [1] - The World Sleep Congress highlights the relationship between sleep, health, and wellness, as well as the prevalence of sleep disorders, particularly insomnia, which affects over 70% of people in Asia [2] Company Insights - ResMed is a key player in the sleep apnea market, primarily generating revenue from CPAP (Continuous Positive Airway Pressure) machines, which are considered the gold standard for treating sleep apnea [3][5] - ResMed is also involved in alternative therapies for sleep apnea, including mandibular devices and nerve stimulation, but emphasizes that CPAP is the most effective treatment for the majority of patients [6][7] Product Developments - Modern CPAP machines have evolved to be smaller, quieter, and more comfortable, with cloud connectivity that enhances patient adherence to therapy [9][10] - Studies indicate that patients using cloud-connected CPAP machines have a significantly higher adherence rate of over 70%, which can increase to over 85% when patients actively engage with their therapy data through an app [10][11] Health Implications - Untreated sleep apnea is linked to increased mortality rates, with a 35% increase in overall mortality and a 55% increase in cardiovascular mortality [11][12] - The condition exacerbates various health issues, including cardiovascular disease, hypertension, and even dementia, highlighting the critical need for awareness and treatment [12]

Core Insights - Resmed has launched the Sleep Institute, a global clinical insights initiative aimed at advancing the science and understanding of sleep health [1][2][3] Group 1: Initiative Overview - The Sleep Institute partners with clinicians, researchers, policymakers, and health system leaders to provide evidence-based insights that inform care innovation and elevate sleep as a global health priority [2][3] - The initiative aims to address the significant underdiagnosis of sleep disorders, particularly obstructive sleep apnea (OSA), which affects an estimated 1 billion people globally [3][5] Group 2: Research and Findings - A U.S. consumer survey revealed that while over 80% of respondents consider sleep important for their health, only one-third have been asked about their sleep by a healthcare professional in the past six months, highlighting a gap in routine healthcare discussions [4][6] - The Sleep Institute will publish original research and real-world data to support earlier and more accurate diagnoses of sleep disorders [3][4] Group 3: Symposium and Collaboration - The Sleep Institute will debut at the World Sleep Congress with a symposium focused on the underdiagnosis of OSA, featuring clinical leaders from various countries [5][6] - The symposium aims to identify barriers in diagnostic pathways and propose scalable solutions to improve access and outcomes in sleep health [5][6] Group 4: Goals and Vision - The overarching goal of the Sleep Institute is to act as a catalyst for earlier diagnosis, stronger policies, and improved outcomes in sleep health worldwide [6][8] - Resmed envisions a future where better sleep and breathing can help individuals achieve their full potential, with care delivered in their homes [9]

Core Insights - The study published in The Lancet Respiratory Medicine indicates a significant rise in obstructive sleep apnea (OSA) in the U.S. over the next three decades, driven by factors such as an aging population and increasing body mass index (BMI) [1][2][3] Group 1: Prevalence Estimates - By 2050, OSA is projected to affect nearly 77 million U.S. adults, a relative increase of nearly 35% from 2020, impacting 46% of adults aged 30-69 [2] - A 65% relative increase in OSA prevalence among women is expected, reaching 30.4 million cases by 2050, highlighting the need for greater awareness of OSA symptoms in women [6] - A 19% relative increase in OSA prevalence among men is anticipated, reaching 45.9 million cases by 2050, indicating ongoing risks in aging male populations [6] Group 2: Health Implications - OSA is linked to serious health issues, including hypertension, cardiovascular disease, diabetes, and stroke, with over 80% of cases remaining undiagnosed and untreated [3] - The study emphasizes the urgent need for earlier diagnosis, preventative strategies, and healthcare resource allocation to address OSA as a major public health concern [3][5] Group 3: Industry Response - The research calls for expanded screening, increased awareness of symptoms, and improved access to testing and treatment, particularly in home settings [4][5] - The anticipated impact of GLP-1 therapies on future OSA prevalence is limited, with reductions estimated at under 5%, indicating that obesity is just one of many contributing factors to OSA [6] - The study serves as a data-driven forecast to help health systems, payers, and policymakers prepare for the growing prevalence of OSA and improve long-term patient outcomes [5][6]

Group 1 - Albert Anthony is a Croatian-American business author and media contributor on investor platforms, with over 1,000 followers on Seeking Alpha [1] - He has a background in IT analysis for Fortune 500 companies and worked in technical support at Charles Schwab in 2021 [1] - Albert Anthony has launched his own equities research firm, Albert Anthony & Company, which operates 100% remotely [1] Group 2 - He is set to release a book titled "Real Estate Investment Trusts (REITs): A Fundamental Analysis" on Amazon in 2025 [1] - Albert Anthony has participated in numerous business and innovation conferences, trade shows, and panel discussions in the EU market, particularly in Croatia [1] - He is currently pursuing the CMSA certification at the Corporate Finance Institute in Vancouver [1] Group 3 - The author does not write about non-publicly traded companies, small cap stocks, or startup CEOs [1] - Albert Anthony's firm is registered as a sole proprietorship in Austin, Texas, and does not provide personalized financial advisory or manage client funds [1] - The author emphasizes that all investment carries risk and encourages readers to conduct their own due diligence [1]

Core Insights - Resmed's AirTouch N30i nasal cradle mask has won two Red Dot Awards for Product Design 2025, highlighting the company's commitment to innovative health technology [1][6] - The mask features a unique fabric-silicone cushion designed for comfort and clinical performance, enhancing user experience in CPAP therapy [2][3] - Resmed aims to improve adherence to therapy for obstructive sleep apnea (OSA), a condition affecting over one billion people globally, by providing innovative solutions like the AirTouch N30i [3][4] Product Features - The AirTouch N30i, launched in October 2024, incorporates a ComfiSoft™ fabric cushion and a breathable frame, ensuring comfort without compromising performance [2] - Its design includes a top-of-head hose connection and a 360-degree rotating elbow, allowing users greater freedom of movement during sleep [2] - In a study, users rated the AirTouch N30i 10 out of 10 for comfort and breathability compared to their previous masks [3][11] Awards and Recognition - The AirTouch N30i has received multiple design awards, including the Australian Good Design Award in September 2024, emphasizing its excellence in improving quality of life [6] - The Red Dot Award is judged by an independent panel of experts, recognizing outstanding products across various dimensions [5] Company Strategy and Vision - Resmed holds a global portfolio of 10,000 patents and designs, reflecting its leadership in sleep and respiratory care and commitment to innovation [4] - The company envisions a future where individuals can achieve better health through improved sleep and breathing, facilitated by accessible home healthcare solutions [7]